Earnings summaries and quarterly performance for OmniAb.
Executive leadership at OmniAb.
Board of directors at OmniAb.
Research analysts who have asked questions during OmniAb earnings calls.
SW
Stephen Willey
Stifel Financial Corp.
4 questions for OABI
Also covers: ABCL, CELC, CGEN +10 more
MH
Matthew Hewitt
Craig-Hallum Capital Group LLC
3 questions for OABI
Also covers: ACET, APYX, BHST +21 more
PS
Puneet Souda
Leerink Partners
3 questions for OABI
Also covers: A, ABCL, BRKR +20 more
BS
Brendan Smith
Stifel, Nicolaus & Company, Incorporated
2 questions for OABI
Also covers: ABCL, ABSI, ARWR +19 more
Joseph Pantginis
H.C. Wainwright & Co.
2 questions for OABI
Also covers: ARMP, BCDA, BLRX +15 more
SD
Srikripa Devarakonda
Truist Financial Corporation
2 questions for OABI
Also covers: ABCL, ABSI, AFMD +12 more
CN
Conor Noel McNamara
RBC Capital Markets
1 question for OABI
Also covers: AVTR, BIO, HOLX +6 more
EC
Eric Carter
RBC Capital Markets
1 question for OABI
Jackson Schroeder
Craig-Hallum Capital Group LLC
1 question for OABI
JK
Jacqueline Kisa
TD Cowen
1 question for OABI
Also covers: ABCL, DNA
KD
Kripa Devarakonda
Truist Securities
1 question for OABI
Also covers: ABCL, ARVN, BMY +5 more
MS
Michael Sonntag
Leerink Partners
1 question for OABI
Recent press releases and 8-K filings for OABI.
OmniAb launches OmniUltra technology
OABI
Product Launch
New Projects/Investments
- OmniAb launched its new OmniUltra technology on December 15, 2025, a transgenic chicken platform designed to discover novel mini-proteins and structured peptides.
- This technology leverages ultra-long CDRH3s (a structural feature typically found in cows) with human sequences, enabling robust immune responses to human targets and expanding OmniAb's offerings beyond traditional antibodies into the growing peptide therapeutic space.
- OmniUltra is anticipated to create new licensing opportunities, increase collaboration and service revenue, and broaden OmniAb's client base to include over 130 companies active in peptide development.
- The platform has already been used in three confidential partner programs and is designed to reduce immunogenicity due to the small, stabilized structure of the derived peptides.
Dec 15, 2025, 10:00 PM
OmniAb Launches OmniUltra Technology
OABI
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- OmniAb launched its new OmniUltra technology on December 15, 2025, which is the first and only transgenic chicken engineered to produce ultra-long cDRH3s for the discovery of novel mini-proteins and structured peptides.
- The OmniUltra platform combines features of cow, human, and avian immune systems, enabling the discovery of therapeutics and expanding OmniAb's capabilities into the peptide therapeutic discovery space.
- This technology allows for the discovery of therapeutic peptides that can be chemically synthesized as standalone peptides, offering a new paradigm for peptide discovery with antibody-like affinity and specificity.
- OmniUltra is expected to open new licensing opportunities, drive collaboration and service revenue, and expand OmniAb's client base to over 130 new companies involved in peptide development, with three early adopter partners already engaged in confidential programs.
Dec 15, 2025, 10:00 PM
OmniAb Launches New OmniUltra Technology for Therapeutic Discovery
OABI
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- OmniAb has launched its new OmniUltra technology, a transgenic chicken platform designed to discover therapeutics, including peptide therapeutics, by producing ultra-long cDRH3s.
- This technology aims to access unique and previously inaccessible epitopes, potentially leading to the isolation of autonomous binding fragments known as Pico bodies.
- OmniAb has already initiated three confidential partner programs using OmniUltra and expects the platform to open new licensing and collaboration opportunities with over 130 new companies in peptide development.
- The company plans to leverage OmniUltra within its existing infrastructure, anticipating no significant incremental investment in sales, marketing, or business development.
Dec 15, 2025, 10:00 PM
Omni Ab Launches OmniUltra
OABI
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Omni Ab (OABI) launched OmniUltra™, a novel transgenic chicken platform that produces antibodies on a human framework with ultralong CDRH3s, designed to reach previously inaccessible binding pockets.
- OmniUltra enables the creation of Picobodies™, the smallest functional antibody fragments, which have broad potential applications including bi-specifics, multi-specifics, binders for CAR-T, radiopharmaceuticals, and peptides.
- This platform expands Omni Ab's opportunities in both antibody and peptide therapeutic discovery, offering biologically-optimized structured peptides and potentially uncovering novel binding domains.
- The launch is expected to significantly increase Omni Ab's potential partner base, adding over 130 peptide companies, and aims to drive higher collaboration/service revenue.
- The total addressable market for OmniUltra's applications, including peptides, bi-specifics, CAR-T, and radiopharma, is estimated to be over $1 trillion by 2034.
Dec 15, 2025, 10:00 PM
OABI reports Q3 2025 results and updates 2025 guidance
OABI
Earnings
Guidance Update
Product Launch
- OABI reported Q3 2025 total revenue of $2.2 million, a decrease from $4.2 million in Q3 2024, with a net loss of ($16.5 million).
- The company updated its 2025 revenue guidance to a range of $18 to $22 million and operating expense guidance to $82 to $86 million, expecting to end the year with $52 to $56 million in cash.
- As of September 30, 2025, OABI continued to grow its business with 104 active partners and 399 active programs.
- A significant new technology, OmniUltra™, is scheduled for launch in December, which is anticipated to open important new markets and business opportunities.
Nov 4, 2025, 9:30 PM
OmniAb Reports Q3 2025 Financial Results, Updates 2025 Guidance, and Announces New Technology Launch
OABI
Earnings
Guidance Update
Product Launch
- OmniAb reported Q3 2025 revenue of $2.2 million and a net loss of $16.5 million, or $0.14 per share.
- The company updated its 2025 financial guidance, now projecting revenue between $18 million and $22 million and operating expenses between $82 million and $86 million.
- OmniAb strengthened its balance sheet by completing a $30 million private placement, netting $28 million, and ended Q3 2025 with $59.5 million in cash.
- The company is launching OmniUltra in December, a new transgenic chicken platform designed to produce cow-like antibodies with ultra-long CDRH3s, which has the potential to open new markets in peptide therapeutics.
Nov 4, 2025, 9:30 PM
OmniAb Announces $30 Million Private Placement
OABI
- OmniAb, Inc. (OABI) announced a definitive securities purchase agreement for a private placement of 21,254,106 shares of its common stock.
- The shares are being sold at a price of $1.40 per share, with officer and director participation at $1.85 per share.
- The private placement is expected to generate approximately $30 million in gross proceeds, which OmniAb intends to use for general corporate purposes and working capital.
- The transaction is anticipated to close on or about August 26, 2025.
Aug 25, 2025, 12:00 AM
Quarterly earnings call transcripts for OmniAb.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more